Literature DB >> 3611795

Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.

L M Muul, K Nason-Burchenal, C S Carter, H Cullis, D Slavin, C Hyatt, E P Director, S F Leitman, H G Klein, S A Rosenberg.   

Abstract

Immunotherapy utilizing the adoptive transfer of lymphokine-activated killer (LAK) cells in conjunction with recombinant interleukin-2 (IL-2) can mediate tumor regression in some patients with advanced cancer. The activation of large numbers of LAK cells was performed in roller bottles in a research laboratory setting and required meticulous aseptic technique, at least one skilled technician per patient and one laminar flow hood per patient. To reduce the complexity and expense of LAK cell generation for human immunotherapy trials we have developed a closed-system automated procedure using a continuous flow blood cell separator. PBL were obtained by standard apheresis techniques. Platelets and plasma were elutriated using countercentrifugal flow of saline in the cell separator machine. The washed PBL were underlaid with Ficoll-Hypaque (FH) in the original separation bag. Lymphocytes were then flushed into a collection bag where they were concentrated and washed with 2 liters of saline. Mean recovery from the automated FH technique was 54.6 +/- 4.3% compared to 62.3 +/- 4.0% using manual methods in 50 ml tubes (P greater than 0.05). Cells were diluted in the collection bag with RPMI 1640 +/- 2% human AB serum and could be dispensed in an automated fashion to polyolefin bags via a sample port with 1000-1500 U/ml IL-2. After 3-4 days of culture in 5% CO2 at 37 degrees C, activated cells from the bags were harvested and washed in a closed system using the continuous flow cell separator. Cell yield from the harvest was 79.2 +/- 5.4% in the automated system compared to 64.9 +/- 5.0% in the standard procedure using manual harvest of roller bottles (P less than 0.01). Lytic capacity of the cells against fresh human tumor in a 4 h 51Cr release assay was equivalent in cells processed either by the automated or the conventional manual method. The advantages of a closed system include decreased potential for microbial contamination and reduced labor and capital equipment costs. This technique may be easily adapted for use with other cell collection and culture systems.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3611795     DOI: 10.1016/0022-1759(87)90148-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.

Authors:  C Fortis; E Ferrero; M Biffi; S Heltai; C Besana; E Bucci; M Tresoldi; C Rugarli
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Simplified long term large scale production of highly active human LAK cells for therapy.

Authors:  P Wersäll; G Masucci; P Pihlstedt; H Wigzell; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

3.  Prospective Evaluation of a Practical Guideline for Managing Positive Sterility Test Results in Cell Therapy Products.

Authors:  Sandhya R Panch; Thejaswi Bikkani; Vanessa Vargas; Jolynn Procter; James W Atkins; Virginia Guptill; Karen M Frank; Anna F Lau; David F Stroncek
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-09       Impact factor: 5.742

Review 4.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

5.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

Review 6.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 7.  Adoptive cell transfer therapy.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

Review 8.  Focus on adoptive T cell transfer trials in melanoma.

Authors:  Liat Hershkovitz; Jacob Schachter; Avraham J Treves; Michal J Besser
Journal:  Clin Dev Immunol       Date:  2010-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.